AfaSci, Inc., is a San Francisco Bay Area based biotech company registered with California, USA. We have been developing two therapeutic candidates with backup compounds for the treatment of neuropathic pain and neuroinflammatory pain. Both analgesic candidates are non-opioid, non-addictive and non-NSAID analgesics. Our pipeline includes new chemical entities (NCEs) for treatment of Alzheimer’s disease, epilepsy and sleep disorders. Our patents of composition of matter and methods of treatment are pending with long patent life.
AfaSci’s competitive advantages include our two drug candidates ready for IND-enabling studies, proprietary drug discovery platform. All our projects were reviewed and supported by NIH SBIR/STTR and R01 grants. AfaSci has a strong research team and established two adjunct units of laboratories, one unit processes cell cultures, electrophysiology (4 setups of patch clamp recordings and multi-electrophysiology array) and histopathology; another Unit hosts animal facility and conducts in vivo pharmacology including EEG/EMG. AfaSci received approval of NIH OLAW Assurance and established an IACUC for conducting animal research, and holds two licenses of Schedule I and Schedule II-V control substances from DEA (Drug Enforcement Administration) permitting to perform comparative studies using opioids and other control substances.
AfaSci has a strong management and scientific team with GlaxoWellcome or Merck in drug discovery and development experience. Our scientific advisors are key opinion leaders in the field. Our research team consists of MD/PhD, PhD or DMD, and scientists trained in electrophysiology and pharmacology. We have established broad academic collaborations including with Stanford University, Harvard University, UCLA, UC Davis, Kansas State University, Pennsylvania State University and SRI International, etc. We also provide contract research services in our expertise areas, and make profit every year since its establishment.
AfaSci is now seeking opportunities to advance our two drug candidates into IND-enabling studies and clinical development with a flexible business model through licensing, investment, joint venture, or outright acquisition.
About the AfaSci Founder, Xinmin Simon Xie, M.D., Ph.D.
Dr. Xie is the founder and Chief Scientific Officer of AfaSci Research Laboratories, established in 2008. He has since led CNS drug discovery, especially in the therapeutic area of neuropathic pain. Dr. Xie received his M.D. from the University of Bern, Switzerland the guidance of Prof. H. Haas and M. Bickel (1989), and Ph.D. in Pharmacology from the University of London, U.K. under supervision of Prof. T. Smart (1992).
Since 2008, Dr. Xie has also served as a Consulting Professor initially in the Department of Medicine and later Anesthesia, Stanford University School of Medicine. He has been an NIH grant reviewer from 2004 to present. He participated in a variety of grant reviews including SBIR/STTR, RO1, R03, R21, S10, P31, U01, and U54.
Dr. Xie has published over 60 peer-reviewed research papers and 5 book chapters, including in Nature, and Science. A List of Published Work is in his Bibliography.